Literature DB >> 16871407

Scleroderma and chronic myeloid leukemia: a sheer coincidence, a consequence of long lasting D-penicillamine therapy or a plausible relationship of both diseases?

Timuçin Kaşifoğlu1, Cengiz Korkmaz, Sule Yaşar, Zafer Gülbaş.   

Abstract

Systemic sclerosis is a chronic multisystem disorder of unknown etiology characterized by the involvement of skin and visceral organs caused by an accumulation of collagen. It has been reported that the incidence of solid and hematological malignancy increased in systemic sclerosis. Multiple myeloma and chronic lymphocytic leukemia are the most common hematological malignancies seen in patients with systemic sclerosis. Chronic myeloid leukemia (CML) has only rarely been reported so far. We here report a case with CREST (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactly, telangiectasia) who developed CML 7 years after the onset of CREST. Ours is the second case with CML developing after the onset of CREST in the literature. We also briefly discuss the possible tendency to hematological malignancy in systemic sclerosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16871407     DOI: 10.1007/s00296-006-0167-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  19 in total

Review 1.  Natural killer cells and natural killer T cells.

Authors:  W E Seaman
Journal:  Arthritis Rheum       Date:  2000-06

2.  Alpha interferon-2a (Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: a pilot study. UK Systemic Sclerosis Study Group.

Authors:  W Stevens; R Vancheeswaran; C M Black
Journal:  Br J Rheumatol       Date:  1992-10

3.  Systemic sclerosis and chronic lymphocytic leukaemia.

Authors:  Y Sidi; R Fadilah; J Pinkhas; M Prokocimer
Journal:  Postgrad Med J       Date:  1990-12       Impact factor: 2.401

4.  [Non-Hodgkin's lymphoma associated with scleroderma].

Authors:  M Pulik; F Teillet-Thiebaud; A Mahe; F Teillet
Journal:  Presse Med       Date:  1991-10-05       Impact factor: 1.228

Review 5.  Chronic myelogenous leukemia and porphyria cutanea tarda in a patient with limited systemic sclerosis.

Authors:  M D Wooten; J W Scott; A M Miller; E Boh
Journal:  South Med J       Date:  1998-05       Impact factor: 0.954

6.  [Generalized scleroderma and chromosome breakage. Demonstration of a breaking factor in patients serum].

Authors:  I Emerit; A Levy; E Housset
Journal:  Ann Genet       Date:  1973-06

7.  Family studies in scleroderma (systemic sclerosis) demonstrating an HLA-linked increased chromosomal breakage rate in cultured lymphocytes.

Authors:  G Rittner; G Schwanitz; M P Baur; C M Black; K I Welsh; P Kühnl; C Rittner
Journal:  Hum Genet       Date:  1988-12       Impact factor: 4.132

Review 8.  Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.

Authors:  F Bonifazi; A de Vivo; G Rosti; F Guilhot; J Guilhot; E Trabacchi; R Hehlmann; A Hochhaus; P C Shepherd; J L Steegmann; H C Kluin-Nelemans; J Thaler; B Simonsson; A Louwagie; J Reiffers; F X Mahon; E Montefusco; G Alimena; J Hasford; S Richards; G Saglio; N Testoni; G Martinelli; S Tura; M Baccarani
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

9.  Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice.

Authors:  M L Grove; A B Hassell; E M Hay; M F Shadforth
Journal:  QJM       Date:  2001-06

10.  Atypical scleroderma associated with multiple myeloma.

Authors:  H Nakanishi; K Takehara; Y Soma; Y Ishibashi
Journal:  Dermatologica       Date:  1989
View more
  4 in total

Review 1.  Myeloid disorders after autoimmune disease.

Authors:  Prajwal C Boddu; Amer M Zeidan
Journal:  Best Pract Res Clin Haematol       Date:  2019-02-07       Impact factor: 3.020

Review 2.  Acute myeloid leukemia developing in patients with autoimmune diseases.

Authors:  Safaa M Ramadan; Tamer M Fouad; Valentina Summa; Syed Kh Hasan; Francesco Lo-Coco
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

3.  Haematological Malignancies in Systemic Sclerosis Patients: Case Reports and Review of the World Literature.

Authors:  M Colaci; D Giuggioli; C Vacchi; C Ferri
Journal:  Case Rep Rheumatol       Date:  2017-05-04

4.  Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China.

Authors:  Shasha Hu; Yong Hou; Qian Wang; Mengtao Li; Dong Xu; Xiaofeng Zeng
Journal:  Arthritis Res Ther       Date:  2018-10-22       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.